Cargando…
Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.
Although osteosclerotic bone metastases are characteristic of prostate cancer, mixed metastases with a lytic component are not uncommon. Type I collagen is synthesised by osteoblasts and accounts for about 90% of the organic matrix of bone. We have used new specific immunoassays for PICP (carboxy-te...
Autores principales: | Kylmälä, T., Tammela, T. L., Risteli, L., Risteli, J., Kontturi, M., Elomaa, I. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033764/ https://www.ncbi.nlm.nih.gov/pubmed/7734300 |
Ejemplares similares
-
Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma.
por: Elomaa, I., et al.
Publicado: (1992) -
Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.
por: Blomqvist, C., et al.
Publicado: (1996) -
Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer.
por: Kylmälä, T., et al.
Publicado: (1997) -
Type III collagen metabolism in soft tissue sarcomas.
por: Wiklund, T. A., et al.
Publicado: (1992) -
Type I and type III collagen metabolites in adult osteosarcoma patients.
por: Wiklund, T., et al.
Publicado: (1996)